Three-dimensional structural analysis of full-length CD20 membrane protein reveals the molecular basis of RTX dual-epitope recognition and its high affinity and CDC activity

The latest research has, for the first time, resolved the three-dimensional structure of the full-length CD20 membrane protein in complex with the RTX Fab, revealing RTX's dual epitope recognition mode for CD20—in addition to the classic primary epitope ECL2 (170ANPSE174), there also exists a secondary epitope formed by ECL1-ECL2.

  • Recent Advances
  • Product Information
Recent Advances

 

Three-Dimensional Structure Analysis of Full-Length CD20 Membrane Protein Reveals the Molecular Basis of RTX Dual-Epitope Recognition and Its High Affinity and CDC Activity

Summary: A recent study has, for the first time, resolved the three-dimensional structure of the full-length CD20 membrane protein in complex with the RTX Fab, revealing a dual-epitope recognition mode of RTX for CD20—in addition to the classic primary epitope ECL2 (170ANPSE174), there also exists a secondary epitope formed by ECL1-ECL2. Mutagenesis experiments confirmed that key residues LC.Ser28 and LC.Ser31 within this secondary epitope directly determine the nanomolar affinity, cell binding, and CDC activity of RTX, establishing the irreplaceable core role of the full-length CD20 membrane protein in therapeutic antibody research.

I. Breakthrough progress has been made in the three-dimensional structure analysis of the full-length CD20 membrane protein in complex with the RTX Fab.

CD20 is a four-transmembrane protein on the surface of B lymphocytes, and high-resolution structural analysis of its full-length form has long faced technical bottlenecks. A recent study successfully obtained the three-dimensional crystal structure of the full-length CD20 membrane protein in complex with the RTX (Rituximab) Fab, achieving a precise depiction of their interaction interface at atomic resolution. In the central region of the complex, RTX heavy-chain Tyr97 simultaneously mediates multiple contacts between Fab-Fab and Fab-CD20, constituting a highly synergistic molecular recognition network (Figure 3A). In addition, additional Fab-Fab interactions are formed among the RTX heavy-chain loop regions H3 and H1 and the light-chain loop region L2 (Figure 3C), further stabilizing the overall conformation of the complex. The resolution of this structure marks the formal transition of CD20-targeted antibody research from the peptide level into the era of full-length membrane proteins.

II. RTX recognition of CD20 involves a dual synergistic mechanism of primary and secondary epitopes.

Previously, the scientific community generally believed that RTX recognizes only the 170ANPSE174 linear sequence on the second extracellular loop (ECL2) of CD20. The new structure reveals a more complex dual-epitope recognition mode: the primary epitope is indeed 170ANPSE174 within ECL2, primarily recognized by the RTX heavy chain; at the same time, this epitope also forms a hydrogen-bond network with the Tyr97′ residue of the distal RTX Fab (Figure 3B). The secondary epitope consists of a three-dimensional conformational surface formed jointly by ECL1 and ECL2, which is specifically contacted by the RTX light-chain loop regions (Figure 3D). This dual recognition mode enables RTX to anchor onto the extracellular domain of CD20 in a unique geometric configuration, explaining the high specificity and stability of its binding.

III. The ECL1-ECL2 secondary epitope is a necessary condition for achieving nanomolar-level affinity.

Using surface plasmon resonance (SPR) technology, the researchers systematically compared the affinity of RTX for the full-length CD20 membrane protein and for the ECL2 polypeptide epitope. The results showed that the affinity of RTX for full-length CD20 reached the nanomolar (nM) level, whereas its affinity for the ECL2 linear polypeptide was significantly reduced. This difference directly demonstrates that the primary epitope alone is insufficient to support the high-affinity binding of RTX, and that the presence of the ECL1-ECL2 secondary epitope is a structural prerequisite for achieving nM-level affinity. In other words, only the natural three-dimensional conformation provided by the full-length CD20 membrane protein can truly present the complete epitope information required for RTX binding.

IV. Mutation of key sites in the secondary epitope produces graded attenuation of RTX function.

To verify the function of the secondary epitope, the researchers performed site-directed mutagenesis on two key residues in the RTX light chain that recognize this epitope. The LC.Ser28 mutation reduced RTX-CD20 affinity by approximately 20-fold, decreased cell binding by approximately 25%, and increased the CDC activity IC50 by more than 10-fold. The LC.Ser31 mutation produced more dramatic effects: affinity plummeted by approximately 100-fold, cell binding decreased by approximately 50%, and CDC activity was almost completely quenched. The graded effects of the two sites indicate that the ECL1-ECL2 secondary epitope not only determines binding affinity but is also the core structural basis for RTX to exert its CDC effector function.

V. The full-length CD20 membrane protein is a core tool for CD20-targeted antibody research.

The above evidence indicates that both the unique binding mode and the efficient CDC activity of RTX are inseparable from the ECL1-ECL2 secondary epitope. Research systems based solely on ECL2 peptides cannot fully reproduce the true picture of antibody-antigen interactions. The full-length CD20 membrane protein, with its complete natural conformational epitope, has become an irreplaceable research tool for the rational design of CD20-targeted antibodies. Against this background, U-AI offers FITC-Labeled CD20 Flag&His Tag Full Length Protein, Human (Detergent), which is based on the natural conformation of the full-length CD20 membrane protein and equipped with a fluorescent label and a dual-tag system, efficiently supporting epitope identification, affinity determination, and functional mechanism studies of CD20-targeted antibodies.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience
Nanjing UNIV Biotechnology Co., Ltd. Email:order@ua-bio.com Phone:+86-25-56221161
公众号
Product Information
The Last The Next